HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.
HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.
More on AGIO
Analyst ratings Benzinga
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $30JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $34 to $30.
